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Abstract
Background: Standardized treatment in pediatric patients with Hodgkin’s lymphoma (HL) follows risk stratification
by tumor stage, erythrocyte sedimentation rate and tumor bulk. We aimed to identify quantitative parameters from
pretherapeutic FDG-PET to assist prediction of response to induction chemotherapy.
Methods: Retrospective analysis in 50 children with HL (f:18; m:32; median age, 14.8 [4–18] a) consecutively treated
according to EuroNet-PHL-C1 (n = 42) or -C2 treatment protocol (n = 8). Total metabolic tumor volume (MTV) in
pretherapeutic FDG-PET was defined using a semi-automated, background-adapted threshold. Metabolic (SUVmax,
SUVmean, SUVpeak, total lesion glycolysis [MTV*SUVmean]) and heterogeneity parameters (asphericity [ASP],
entropy, contrast, local homogeneity, energy, and cumulative SUV-volume histograms) were derived. Early response
assessment (ERA) was performed after 2 cycles of induction chemotherapy according to treatment protocol and
verified by reference rating. Prediction of inadequate response (IR) in ERA was based on ROC analysis separated by
stage I/II (1 and 26 patients) and stage III/IV disease (7 and 16 patients) or treatment group/level (TG/TL) 1 to 3.
Results: IR was seen in 28/50 patients (TG/TL 1, 6/12 patients; TG/TL 2, 10/17; TG/TL 3, 12/21). Among all PET parameters,
MTV best predicted IR; ASP was the best heterogeneity parameter. AUC of MTV was 0.84 (95%-confidence interval,
0.69–0.99) in stage I/II and 0.86 (0.7–1.0) in stage III/IV. In patients of TG/TL 1, AUC of MTV was 0.92 (0.74–1.0); in
TG/TL 2 0.71 (0.44–0.99), and in TG/TL 3 0.85 (0.69–1.0). Patients with high vs. low MTV had IR in 86 vs. 0% in TG/TL 1,
80 vs. 29% in TG/TL 2, and 90 vs. 27% in TG/TL 3 (cut-off, > 80 ml, > 160 ml, > 410 ml).
Conclusions: In this explorative study, high total MTV best predicted inadequate response to induction therapy in
pediatric HL of all pretherapeutic FDG-PET parameters – in both low and high stages as well as the 3 different TG/TL.
Trial registration: Ethics committee number: EA2/151/16 (retrospectively registered).
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Background
Hodgkin’s lymphoma (HL) accounts for about 7% of
pediatric malignancies and about 1% of childhood
cancer-related deaths in the United States [1]. Treatment
intensity within standardized treatment protocols is
based on different treatment groups/treatment levels
(TG/TL) defined by the clinical stages I to IV, the pres-
ence of extranodal lesions, elevated erythrocyte sedimen-
tation rate (ESR, ≥ 30 mm/h) or a tumor bulk ≥ 200 ml
[2, 3]. F18-fluorodesoxyglucose-positron emission tom-
ography/computed tomography (FDG-PET/CT) allows
for combined functional-metabolic and morphological
imaging both at initial staging to define the patient’s
clinical stage [4] and during treatment to assess the
presence or absence of remaining vital lymphoma tissue
[5–7]. In particular, FDG-PET/CT has become essential
for early response assessment (ERA) performed after
2 cycles of induction therapy [2, 3, 5]; only if FDG-avid
tissue is still present in initially involved sites (semi-
quantified as Deauville score > 3 or quantified with qPET
[6]) or bulky lesions show < 50% volume reduction in
CT, patients in all TG/TL are currently eligible for radio-
therapy (RT) dependent on late response assessment fol-
lowing further chemotherapy. In patients with adequate
response (AR), RT can be omitted irrespective of the TG/
TL – and late effects due to radiotherapy, especially sec-
ondary malignancies, are avoided [8, 9]. Nevertheless, pre-
diction of OS by ERA may inferior to late response
assessment (LRA) [10]. Furthermore, initial prediction of
response to induction therapy could even allow individual-
ized treatment intensification to prevent IR a priori.
Despite this important role of FDG-PET/CT, no initial
PET based parameter has been identified so far to pre-
dict response at ERA in pediatric HL patients – includ-
ing the standardized uptake value (SUV) as the most
common quantitative FDG-PET parameter [11]. Never-
theless, Meignan et al. recently showed in adult patients
with follicular lymphoma (mostly stage III or IV disease)
that a high initial metabolic tumor volume (MTV) can
predict progression-free survival (PFS) and overall sur-
vival (OS) [12]. Moreover, Ben Bouallègue et al. demon-
strated that heterogeneity parameters derived from the
delineated MTV can serve as additional predictors of
early metabolic response in adults with bulky Hodgkin
and non-Hodgkin lymphomas [13].
Accordingly, the aim of this study was to identify
metabolic or heterogeneity parameters from prethera-
peutic FDG-PET/CT to predict inadequate response (IR)
in pediatric patients with HL. PFS or OS were not
selected as endpoints in this study because both are not
only determined by initial characteristics/risk profile
(which was the main focus of this study) but also by




This retrospective study included 50 consecutively ex-
amined children with classical HL (female, n = 18; male,
n = 32; median age, 14.8 years; range, 4.0 to 18.0 years)
treated according to EuroNet-PHL-C1 (n = 42) or -C2
treatment protocol (n = 8) between 2007 and 2017 [2, 3].
It included 31 patients with nodular sclerosing type and
17 patients with mixed cellularity type (not further spe-
cified, n = 2). These protocols are consecutive multi-
national standardized treatment protocols for pediatric
patients with HL (lymphocyte-predominant subtype ex-
cluded). All patients undergo two cycles of induction
chemotherapy (OEPA) before ERA with FDG-PET/CT is
performed. This is followed by further chemotherapy
(none in TG 1, one cycle in TL 1 with AR, two to four
cycles in TG/TL 2 or 3) and, most importantly, deter-
mines the necessity of additional radiation therapy of the
initially involved regions (all TG/TL in case of IR). In
TG/TL 2 or 3, additional LRA is conducted after the
second treatment segment in patients with IR at ERA to
decide on further intensification of the subsequent radi-
ation therapy [2, 3].
In patients diagnosed before November 2012, TG 1 in-
cluded stage I and IIA without extranodal disease, TG 2
covered stage I or IIA with extranodal disease and any
stage IIB or IIIA, and TG 3 included stage IIB or IIIA with
extranodal disease and any stage IIIB or IV [2]. In patients
diagnosed after November 2012, TL 1 covered patients
with stage I and IIA without any risk factor while TL 2 in-
cluded stage I or IIA with elevated ESR or bulk or extra-
nodal disease and any stage IIB or IIIA without extranodal
disease. TL 3 covered stage IIB or IIIA with extranodal
disease and any stage IIIB or IV [2, 3].
Positron emission tomography/computed tomography
(PET/CT)
PET/CT imaging was performed using the tracer FDG
and a dedicated PET/CT device (Gemini TF 16; Philips,
Amsterdam, The Netherlands) with Philips Astonish TF
technology. FDG was administered intravenously using a
weight-adapted activity (median, 250 MBq; interquartile
range [IQR], 170 to 275 MBq) based on recommenda-
tions provided by the European Association of Nuclear
Medicine (EANM) [14]. A test of blood glucose level
was mandatory to assure that blood glucose level was
≤8.3 mmol/l. The PET scan was performed after a me-
dian uptake time of 63 min (IQR, 57 to 76 min) in su-
pine position from base of skull to the proximal femora
with an axial field of view of 180 mm (3D mode; bed
overlap, 53.3%). Attenuation correction was either based
on contrast-enhanced CT (n = 33; automatic tube
current modulation; weight-dependent maximum tube
current, 100 to 200 mA; tube voltage, 120 kV; gantry
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rotation time, 0.5 s) or non-enhanced low-dose CT (n = 17;
automatic tube current modulation; maximum tube
current, 80 mA; tube voltage, 120 kV; gantry rotation time,
0.5 s). PET raw data was reconstructed iteratively with
TOF analysis (BLOB-OS-TF; iterations, 3; subsets, 33;
Philips Astonish TF technology). Projection data was
reconstructed with 4 mm slice thickness (rows, 144;
columns, 144; voxel size, 4x4x4 mm).
Quantitative FDG-PET analysis
Quantification of FDG-PET data was performed with
dedicated software (ROVER, version 3.0.34, ABX ad-
vanced biochemical compounds GmbH, Radeberg,
Germany). All analysis was performed blinded to the re-
sults of ERA; however, the identification of HL lesions
comprised all clinical and imaging data available in the
pre-treatment setting including the final tumor stage as
defined by interdisciplinary consensus (nuclear medicine
physician, pediatric radiologist, pediatric oncologist, radi-
ation oncologist, pediatric surgeon). The combined MTV
of the entire FDG-avid HL lesion load of the patient
(nodal and extranodal disease) was delineated using a
semi-automatic, background-adapted algorithm [15, 16]
(Fig. 1). The first step involved delineation on a per-lesion
basis, visual inspection and manual correction if this
deemed necessary. Manual correction (i.e. manually ad-
justed threshold or separate delineation of subvolumes)
was necessary for 87 of 624 lesions (13.9%) affecting 26 of
50 patients. Manual correction was performed either for
lesions with relatively low activity concentration compared
to other lesions in the same body compartment that had
to be delineated in a separate subvolume (83 of 624
lesions; 26 of 50 patients) or for lesions with highly
heterogeneous intralesional activity concentration that re-
quired subdivision of the lesion (4 of 624 lesions; 3 of 50
patients). Bone marrow involvement was only diagnosed
by PET if focal uptake could be clearly delineated.
After delineation of all individual lesions in one patient,
the entirety of these lesional MTV was regarded as the
patient’s total MTV which was exclusively used for final
analysis and to derive all other parameters. As further
metabolic parameters the SUVmax, SUVmean, SUVpeak
(mean value of a spherical ROI with a diameter of
approximately 1.2 cm centered at the ROI maximum) and
total lesion glycolysis (TLG; MTV*SUVmean) were calcu-
lated for the whole MTV. Heterogeneity parameters were
derived including the asphericity (ASP) [17, 18], entropy,
energy, contrast, local homogeneity [19, 20], and cumula-
tive SUV-volume histograms (CSH) [21, 22].
For comparative analysis (see Additional file 1),
the MTV in all patients was also delineated with a
fixed relative threshold of 41% of the maximum
activity (MTVt41) and a fixed absolute threshold of
SUV = 2.5 (MTV2.5).
Early response assessment (ERA)
ERA was performed according to the respective treat-
ment protocol after 2 cycles of induction chemotherapy.
In patients treated according to EuroNet-PHL-C1
protocol [2], IR was assigned if no overall complete re-
sponse on morphological imaging was seen and any ini-
tially involved site was still PET-positive (based on
International Harmonization Project criteria [23]); IR
was also defined if no change was seen in morphological
imaging (irrespective of PET) or if disease was still de-
tectable on morphological imaging and PET was unclear.
According to EuroNet-PHL-C2 protocol [3], IR in these
patients was assigned if at least one site showed remaining
FDG uptake higher than liver uptake on visual assessment
(Deauville ≥ 4) or showed a qPET value ≥ 1.3 [6] or in case
of poor bulk response (< 50% volume reduction) or if any
nodal site with a diameter of ≥ 2 cm was nonassessable
with qPET analysis. AR was assigned if IR criteria were
not fulfilled and no disease progression was present. The
assessment was verified by reference rating provided by
the study group.
Fig. 1 Patient examples of low and high MTV. Representative
examples of FDG-PET maximum intensity projections (MIP) of two
patients with stage IV disease before induction therapy (a, b+ d, e) and
at ERA (c, f). In the middle column (b, e), the delineated pretherapeutic
MTV is colored (high activity: white, low activity: brownish).
a-c: A 17-year-old male with stage IV disease (liver, lung) and AR who
had a low MTV (51 ml). d-f: A 17-year-old male with stage IV disease
(skeletal) and IR who showed a high MTV (792 ml); please also note
the large lymph node mass at the liver hilus (red arrow) and extensive
splenic involvement (green arrow). At ERA, considerable FDG uptake
(Deauville score 4) can still be detected especially in a left axillary
lymph node and the left humerus (blue arrows)
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Statistical analysis
Statistical analysis was performed using SPSS 22 (IBM
Corporation, Armonk, NY, USA). Descriptive parameters
were expressed as median, IQR and range or 95%-
confidence interval (95%-CI), unless otherwise specified.
Optimal cut-off values for quantitative FDG-PET parame-
ters to distinguish IR from AR were defined by receiver
operating characteristic (ROC) curves with respective
areas under the curve (AUC). The optimal cut-off value
was defined as the point on the ROC curve with the min-
imal distance d to the point (0,1) calculated as follows:
d ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−Sensitivityð Þ2 þ 1−Specificityð Þ2
q
Patients were divided into groups of stages I/II versus
III/IV and, alternatively, based on the assigned treatment
group or treatment level (TG/TL) 1 versus 2 versus 3 ac-
cording to the respective treatment protocol. Differences
in MTV and ASP between these groups were investi-
gated with Mann-Whitney U test. The relationship
between a high MTV or high ASP, respectively, the
patient’s tumor stage (I/II vs. III/IV) or TG/TL, and the
result of ERA (IR vs. AR) was further assessed with log-
linear analysis. Statistical significance was assumed at a
p ≤ 0.05.
Results
One of 50 patients had stage I, 26 patients had stage II, 7
patients had stage III, and 16 patients had stage IV disease
(Table 1). Twelve patients were assigned TG/TL 1, 17 pa-
tients TG/TL 2, and 21 patients were assigned TG/TL 3. IR
was observed in 28 of 50 patients, including 6 of 12 patients
of TG/TL 1, 10 of 17 patients of TG/TL 2, and 12 of 21 pa-
tients of TG/TL 3.
Metabolic and heterogeneity parameters in relation to
stage and TG/TL
Median MTV was 7.0 ml in stage I (one patient only),
154.0 ml (IQR, 73.9 to 194.2 ml) in stage II, 386.2 ml
(137.9 to 537.8 ml) in stage III, and 350.6 ml (207.4 to
555.9 ml) in stage IV patients (Fig. 2) with significant
differences only between stages II and III (p = 0.01).
Comparison with stage I was not performed as it only
included one patient. ASP in stage I was 22.2%, in stage
II it was 137.9% (87.4 to 179.1%), in stage III 195.5%
(121.7 to 236.4%), and in stage IV it was 224.9% (190.1
to 306.3%); no significant differences were detected.
Among the remaining metabolic and heterogeneity pa-
rameters, only TLG was significantly different between
stage II and III (p = 0.009).
The median MTV in TG/TL 1 was 87.4 ml (29.3 to
138.9 ml) compared to TG/TL 2 with 177.4 ml (103.4
to 221.0 ml) and TG/TL 3 with 375.8 ml (213.9 to
555.3 ml). MTV was significantly higher in TG/TL 3
vs. TG/TL 2 vs. TG/TL 1 patients (each p < 0.01). ASP in
TG/TL 1 was 136.8% (77.4 to 206.3%) compared to 136.2%
(91.2 to 165.3%) in TG/TL 2 (p = 0.95) and TG/TL 3 with
231.0% (189.7 to 290.3%). ASP in TG/TL 3 patients was
significantly higher compared to TG/TL 1 or TG/TL 2 pa-
tients (each p < 0.01). Among the remaining parameters, a
significant difference between TG/TL 1 vs. 2 was measured
for SUVmax, SUVmean, SUVpeak, TLG, contrast, and local
homogeneity (each p < 0.05). Significant differences be-
tween TG/TL 2 vs. 3 were observed for TLG, entropy, con-
trast, local homogeneity, energy, and CSH (each p < 0.05).
Prediction of IR – different stages
MTV showed the highest AUC of all PET parameters;
AUC for MTV in patients with stage I/II was 0.84
(95%-CI, 0.69 to 0.99), AUC in patients with stage III/IV
was 0.86 (0.7 to 1.0). Using the respective optimal cut-off
Table 1 Patient characteristics
Parameter All patients (%) Patients with IR (%) Patients with AR (%)
Total 50 28 22
Sex
Female 18 (36) 12 (43) 6 (27)
Male 32 (64) 16 (57) 16 (73)
Stage
I 1 (2) 0 1 (5)
II 26 (52) 16 (57) 10 (45)
III 7 (14) 2 (7) 5 (23)
IV 16 (32) 10 (36) 6 (27)
TG/TL
1 12 (24) 6 (21) 6 (27)
2 17 (34) 10 (36) 7 (32)
3 21 (42) 12 (43) 9 (41)
ESR ≥ 30 mm/h
Yes 33 (66) 19 (68) 14 (64)
No 17 (34) 9 (32) 8 (36)
Bulk ≥ 200 ml
Yes 17 (34) 12 (43) 5 (23)
No 33 (66) 16 (57) 17 (77)
B-symptoms
Yes 23 (46) 12 (43) 11 (50)
No 27 (54) 16 (57) 11 (50)
Extranodal
Yes 8 (16) 4 (14) 4 (18)
No 42 (84) 24 (86) 18 (82)
Protocol
PHL-C1 42 (84) 25 (89) 17 (77)
PHL-C2 8 (16) 3 (11) 5 (23)
IR inadequate response, AR adequate response, TG/TL treatment group/level,
ESR erythrocyte sedimentation rate
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value (stage I/II, > 80 ml; stage III/IV, > 410 ml), patients
with high vs. low MTV showed IR in 78.9 vs. 12.5% in
stage I/II as well as 90.0 vs. 23.1% in stage III/IV. Sensitiv-
ity, specificity, negative predictive value (NPV), and posi-
tive predictive value (PPV) to predict IR were 94, 64, 88,
and 79% in stage I/II compared to 75, 91, 77, and 90% in
stage III/IV (Tables 2 and 3). Log-linear analysis showed a
significant relationship between a high MTV and the
response to induction therapy (IR vs. AR; z value, 3.9;
p < 0.001) but not between tumor stage (I/II vs. III/IV)
and MTV or response to therapy (both p > 0.05).
Among heterogeneity parameters only, ASP provided
the highest AUC in patients with stage I/II of 0.65 (0.43
to 0.88) and in stage III/IV of 0.74 (0.54 to 0.95; Tables 2
and 3). There was a significant relationship between high
ASP and the response to induction therapy (z value, 2.8;
p < 0.01) but not between tumor stage and ASP or re-
sponse to therapy (both p > 0.05).
Fig. 2 Box plots for MTV and ASP in different stages and TG/TL. In the upper row, box plots for MTV and ASP are separated only by different
stages or TG/TL; significant differences between subgroups are highlighted (*p < 0.05; **p < 0.01; ***p < 0.001). Please note that only one patient
had stage I disease which was therefore excluded from comparison. In the lower row, box plots are further separated by AR (dark grey) or IR
(light grey); due to the smaller sample size, significance of the differences was not tested. ASP, asphericity; MTV, metabolic tumor volume, TG/TL,
treatment group/level
Table 2 Results of ROC analysis separated by stage
Stage I/II Stage III/IV
AUC (95%-CI) Optimal cut-off value AUC (95%-CI) Optimal cut-off value
Metabolic parameters
MTV 0.84 (0.69 to 0.99) > 80 ml 0.86 (0.7 to 1.0) > 410 ml
SUVmax 0.56 (0.33 to 0.8) > 10.2 0.71 (0.5 to 0.93) > 13.8
SUVmean 0.61 (0.39 to 0.83) > 4.1 0.71 (0.5 to 0.93) > 5.9
SUVpeak 0.58 (0.35 to 0.81) > 9.1 0.74 (0.53 to 0.95) > 12.6
TLG 0.77 (0.58 to 0.97) > 450 ml 0.86 (0.7 to 1.0) > 2800 ml
Heterogeneity parameters
ASP 0.65 (0.43 to 0.88) > 92% 0.74 (0.54 to 0.95) > 210%
Entropy 0.58 (0.35 to 0.81) < 5.82 0.58 (0.33 to 0.82) < 5.73
Contrast 0.67 (0.45 to 0.89) < 25 0.66 (0.43 to 0.89) < 16
Local homogeneity 0.58 (0.33 to 0.83) > 24 0.68 (0.45 to 0.91) > 30.4
Energy 0.58 (0.34 to 0.82) > 0.394 0.55 (0.31 to 0.8) > 0.51
CSH 0.49 (0.25 to 0.74) > 0.44 0.46 (0.21 to 0.7) > 0.44
MTV metabolic tumor volume, 95%-CI 95%-confidence interval, TLG total lesion glycolysis, ASP asphericity, CSH cumulative SUV-volume histograms
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Prediction of IR – different treatment groups/levels
The average AUC across all TG/TL was highest for MTV;
AUC was 0.92 (0.74 to 1.0) for TG/TL 1, 0.71 (0.44 to 0.99)
for TG/TL 2, and 0.85 (0.69 to 1.0) for TG/TL 3. Patients
with high vs. low MTV had IR in 85.7 vs. 0% in TG/TL
1 (optimal cut-off, > 80 ml), 80.0 vs. 28.6% in TG/TL 2
(cut-off, > 160 ml), and 90.0 vs. 27.3% in TG/TL 3 (cut-
off, > 410 ml). Sensitivity, specificity, NPV, and PPV of
MTV to predict IR in TG/TL 1 were 100, 83, 100, and
86% compared to 80, 71, 71, and 80% in TG/TL 2 and
75, 89, 73, and 90% in TG/TL 3 (Tables 4 and 5). The
relationship between high MTV and response to
therapy was significant in log-linear analysis (z value, 3.7;
p < 0.001) but not the relation between TG/TL and MTV
or the response to therapy (both p > 0.05).
Among the heterogeneity parameters, ASP provided the
highest AUC in patients within TG/TL 1 of 0.78 (0.49 to
1.0) compared to 0.5 (0.2 to 0.8) in TG/TL 2 and to 0.7 (0.48
to 0.93) in TG/TL 3 (Tables 4 and 5). There was a
significant relationship between high ASP and the re-
sponse to therapy (z value, 2.6; p < 0.01) but not between
TG/TL and ASP or response to therapy (both p > 0.05).
Patients with either high ASP or MTV vs. patients with
both low MTV and ASP had IR in 85.7 vs. 0% (TG/TL 1),
71.2 vs. 0% (TG/TL 2), and 76.9 vs. 25% (TG/TL 3).
Discussion
The aim of the present study was to investigate the pre-
dictive value of several quantitative parameters derived
from pretherapeutic FDG-PET in pediatric HL regarding
the occurrence of IR at ERA after induction therapy.
The total MTV of all nodal and extranodal HL lesions
of the patients predicted IR with high but varying accuracy
within all three TG/TL (AUC, 0.71 to 0.92). Furthermore,
the optimal cut-off to distinguish patients with IR or AR
was distinctly different between either stages I/II versus
III/IV (cut-off, > 80 ml vs. > 410 ml) or between the three
TG/TL (> 80 ml vs. > 160 ml vs. > 410 ml). This reflects
Table 3 Diagnostic accuracy of MTV and ASP towards IR (stages)
Stage I/II Stage III/IV
Parameter Sens. (95%-CI) Spec. (95%-CI) Sens. (95%-CI) Spec. (95%-CI)
NPV (95%-CI) PPV (95%-CI) NPV (95%-CI) PPV (95%-CI)
MTV 94% (70 to 100%) 64% (31 to 89%) 75% (43 to 95%) 91% (59 to 100%)
88% (47 to 100%) 79% (54 to 94%) 77% (46 to 95%) 90% (55 to 100%)
ASP 81% (54 to 96%) 55% (23 to 83%) 83% (52 to 98%) 64% (31 to 89%)
67% (30 to 93%) 72% (47 to 90%) 78% (40 to 97%) 71% (42 to 92%)
Sens. sensitivity, 95%-CI 95%-confidence interval, spec. Specificity, NPV negative predictive value, PPV positive predictive value, MTV metabolic tumor volume,
ASP asphericity
Table 4 Results of ROC analysis separated by TG/TL
TG/TL 1 TG/TL 2 TG/TL 3
AUC (95%-CI) Optimal cut-off value AUC (95%-CI) Optimal cut-off value AUC (95%-CI) Optimal cut-off value
Metabolic parameters
MTV 0.92 (0.74 to 1.0) > 80 ml 0.71 (0.44 to 0.99) > 160 ml 0.85 (0.69 to 1.0) > 410 ml
SUVmax 0.47 (0.1 to 0.86) > 7.5 0.61 (0.29 to 0.94) > 13.9 0.67 (0.43 to 0.91) > 13.8
SUVmean 0.39 (0.0 to 0.76) > 3.3 0.73 (0.49 to 0.97) > 6.6 0.69 (0.46 to 0.93) > 5.9
SUVpeak 0.42 (0.0 to 0.79) > 5.3 0.6 (0.28 to 0.92) > 12.3 0.71 (0.48 to 0.94) > 12.6
TLG 0.89 (0.7 to 1.0) > 320 ml 0.66 (0.38 to 0.93) > 890 ml 0.85 (0.69 to 1.0) > 2800 ml
Heterogeneity parameters
ASP 0.78 (0.49 to 1.0) > 137% 0.5 (0.2 to 0.8) > 90% 0.7 (0.48 to 0.93) > 235%
Entropy 0.61 (0.27 to 0.95) < 5.9 0.53 (0.22 to 0.84) < 5.82 0.51 (0.25 to 0.77) < 5.73
Contrast 0.78 (0.51 to 1.0) < 39 0.54 (0.24 to 0.85) < 17.6 0.61 (0.35 to 0.87) < 19
Local homogeneity 0.67 (0.34 to 1.0) > 21.8 0.43 (0.11 to 0.75) > 23.3 0.64 (0.38 to 0.9) > 30.4
Energy 0.58 (0.23 to 0.93) > 0.37 0.54 (0.23 to 0.85) > 0.41 0.48 (0.22 to 0.75) > 0.51
CSH 0.33 (0.0 to 0.67) > 0.52 0.63 (0.32 to 0.94) > 0.44 0.51 (0.25 to 0.77) > 0.41
TG/TL treatment group / level, 95%-CI 95%-confidence interval, MTV metabolic tumor volume, TLG total lesion glycolysis, ASP asphericity, CSH cumulative
SUV-volume histograms
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an increasing average MTV especially between stage I/II
and stage III/IV disease as one expects given the supposed
increase in involved regions – while, interestingly, the
average MTV in stage III and stage IV was similar (Fig. 2).
This study shows that quantitative parameters from
pretherapeutic FDG-PET can predict IR to induction
therapy in pediatric HL. This could help to further im-
prove the established risk stratification. Patients with a
high risk for IR could benefit from more intense induc-
tion therapy to increase their probability of achieving
AR and avoid additional radiation therapy. Vice versa,
patients with a priori especially low risk for IR might be
the best candidates for the pursued treatment de-
escalation. With regard to the patient’s outcome, Cotter-
eau et al. demonstrated that the baseline MTV in adult
patients with peripheral T-cell lymphoma (PTCL) helps
to predict PFS and OS [24]. Both Cottereau et al. and
Meignan et al. [12] delineated the MTV based on 41% of
the maximum activity (i.e. t41 in the Supplementary ma-
terial of the present study). However, Cottereau et al.
further showed that a fixed threshold of 41% of max-
imum activity and different adaptive thresholds render
highly correlative MTV and equally predict PFS and OS
in patients with PTCL [25]. In the current study, the
MTV was primarily defined using a background-adapted
semi-automated algorithm (BG) but comparison with
t41 confirmed this high inter-method agreement in mea-
sured MTV and ASP (see Additional file 1). In contrast,
agreement with an absolute threshold of SUV = 2.5 was
lower. However, larger patient samples would be re-
quired to evaluate if one of the methods is significantly
more accurate to predict the patient’s outcome. In a
study by Kanoun et al. with 59 mainly adult HL patients,
MTV delineated with a 41% relative threshold or a fixed
SUV of 2.5 equally allowed to identify patients with
impaired PFS despite considerable inter-method MTV
differences [26]. Nevertheless, advantageous practicality or
robustness might favor one of the delineation approaches.
Only BG and t41 allow for a differentiated delineation of le-
sions taking into account their intralesional and interle-
sional uptake heterogeneity – which is especially true for
BG (see [16] for details). However, this might prolongate
the delineation process if neighboring lesions within a sub-
volume (e.g. the mediastinum) are especially heterogeneous.
An absolute SUV threshold disregards such heterogeneities
which can facilitate lesion delineation despite the necessity
to adjust the absolute SUV level in high background activity
(e.g. spleen or bones) or to manually exclude background
voxels from the MTV. For background-adapted MTV de-
lineation, we used an algorithm developed at our site, but
several other viable automated algorithms have been pub-
lished [27–35]. It can be assumed that these algorithms per-
form similar to the algorithm used here.
Further metabolic parameters performed slightly
(TLG) or considerably worse (different SUVs) compared
to the MTV. This is in accordance with a study by
Bouallègue et al. who did not find an association be-
tween SUVmax, SUVmean or SUVpeak with the early
metabolic response in 57 patients (mostly adults) with
HL or non-Hodgkin lymphoma [13]. The observation
that the FDG uptake intensity in HL lesions is of less
relevance than the anatomical distribution or volumetric
extent of the lesions might be attributed to the multi-
focal/systemic nature of HL in contrast to other
childhood malignancies such as Ewing’s sarcoma [36] or
osteosarcoma [37] in which the pre-treatment SUVmax
is a prognostic factor. Furthermore, the examined het-
erogeneity parameters – among which the ASP still per-
formed best – showed lower predictive accuracy on
average than the MTV. Except for the ASP, none of the
heterogeneity parameters provided consistent predictive
value sufficient for clinical application. Similarly, in the
study by Ben Bouallègue et al., entropy, contrast and
CSH were no significant predictors of early metabolic re-
sponse (neither was the ASP) [13]. To estimate why cer-
tain heterogeneity parameters are especially relevant in
different tumor entities requires thorough consideration
of methodological (spatial resolution, voxel size), bio-
logical (lesion number and sizes), and metabolic features
(intralesional heterogeneity of FDG uptake intensity).
The examined heterogeneity parameters are differently
susceptible to these factors. More specifically, the ASP is
a priori independent not only from the size of the MTV it-
self but also from the heterogeneity of the intralesional
Table 5 Diagnostic accuracy of MTV and ASP towards IR (TG/TL)
TG/TL 1 TG/TL 2 TG/TL 3
Parameter Sens. (95%-CI) Spec. (95%-CI) Sens. (95%-CI) Spec. (95%-CI) Sens. (95%-CI) Spec. (95%-CI)
NPV (95%-CI) PPV (95%-CI) NPV (95%-CI) PPV (95%-CI) NPV (95%-CI) PPV (95%-CI)
MTV 100% (54 to 100%) 83% (36 to 100%) 80% (44 to 97%) 71% (29 to 96%) 75% (43 to 95%) 89% (52 to 100%)
100% (48 to 100%) 86% (42 to 100%) 71% (29 to 96%) 80% (44 to 97%) 73% (39 to 94%) 90% (55 to 100%)
ASP 83% (36 to 100%) 67% (22 to 96%) 80% (44 to 97%) 43% (10 to 82%) 58% (28 to 85%) 78% (40 to 97%)
80% (28 to 99%) 71% (29 to 96%) 60% (15 to 95%) 67% (35 to 90%) 58% (28 to 85%) 78% (40 to 97%)
TG/TL treatment group/level, Sens. sensitivity, 95%-CI 95%-confidence interval, spec. Specificity, NPV negative predictive value, PPV positive predictive value,
MTV metabolic tumor volume, ASP asphericity
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activity distribution (it only depends on the MTV’s surface
complexity). Thus, it could in principal be valuable as an
additional quantitative parameter to the MTV to improve
the predictive value of pretherapeutic PET in pediatric HL
in all or only some of the different TG/TL. This combined
risk assessment could especially help to increase the sensi-
tivity to identify patients at risk for IR which is likely the
primary clinical goal. Both parameters were significantly re-
lated to the response to induction therapy when evaluated
in separate models (log-linear analysis); however, the evalu-
ation of an independent predictive relevance of both pa-
rameters in a combined analysis would require a larger
sample size. This is also true for the relationship between
MTV and ASP with the tumor stage or TG/TL.
This retrospective explorative study is limited by the
investigation of only 50 patients (although treated con-
secutively) which necessitates a larger study with an in-
dependent patient cohort to validate the presented
results and to further elucidate the predictive value of
single parameters within the relevant subgroups. Fur-
thermore, as only one patient had stage I, no specific
conclusions can be drawn for this stage in particular.
The response to induction therapy at ERA was used as
endpoint in the current study but is only a surrogate for pa-
tient outcome – as opposed to the PFS or OS. Indeed, the
predictive value of a high pretherapeutic MTV independent
from the German Hodgkin Study Group (GHSG) risk group
has been recently demonstrated retrospectively in 267 adult
patients with early stage HL [38]. Nevertheless, one must be
aware that a long-term endpoint as PFS or OS implies a cer-
tain bias of response-dependent treatment intensification
(namely radiotherapy) that can only be avoided by a pro-
spective study design or an early universal surrogate param-
eter such as the IR to a uniform induction treatment.
Conclusions
In this explorative study, a high total MTV best predicted
IR to induction therapy in pediatric HL of all pretherapeu-
tic FDG-PET parameters. This was true in both low and
high stages as well as the three different TG/TL. Among
the investigated heterogeneity parameters, only ASP may
be sufficiently predictive of IR to serve as a supplemental
parameter to the MTV and further improve the predictive
accuracy. The influence of inter-method MTV variability
of different delineation approaches on their predictive ac-
curacy requires further investigation.
Additional file
Additional file 1: Supplemental materials. Results of additional analysis
on delineation with a fixed relative threshold (MTVt41) and a fixed
absolute threshold (MTV2.5) in comparison with the background-adapted
semi-automated delineation presented in the main manuscript (MTVBG)
[39]. (DOCX 3060 kb)
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